Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience

Date
2020
Author
Cil, I
EKENEL, Meltem
Zirtiloglu, A.
Karabulut, S.
Tural, D.
Aydin, E.
Metadata
Show full item record
Abstract
Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.
URI
http://hdl.handle.net/20.500.12627/155211
https://doi.org/10.1016/j.acuro.2019.06.007
Collections